Nothing Special   »   [go: up one dir, main page]

TNSN02009A1 - Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant. - Google Patents

Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.

Info

Publication number
TNSN02009A1
TNSN02009A1 TNTNSN02009A TNSN02009A TNSN02009A1 TN SN02009 A1 TNSN02009 A1 TN SN02009A1 TN TNSN02009 A TNTNSN02009 A TN TNSN02009A TN SN02009 A TNSN02009 A TN SN02009A TN SN02009 A1 TNSN02009 A1 TN SN02009A1
Authority
TN
Tunisia
Prior art keywords
mmp
inhibitors
compositions containing
condensed bicyclic
new condensed
Prior art date
Application number
TNTNSN02009A
Other languages
English (en)
Inventor
Glen Harter William
Jack Li Jie
Fred Ortwine Daniel
Ray Shuler Kevon
Yue Wen-Song
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TNSN02009A1 publication Critical patent/TNSN02009A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L’INVENTION A POUR OBJET DES COMPOSES DE FORMULE : DANS LAQUELLE R1, R4,ET Y REPRESENTENT DIVERS RADICAUX, ET W, CONJOINTEMENT AVEC LES ATOMES DE CARBONE AUQUEL IL EST FIXE, FORME UN DIRADICAL A NOYAU PENTAGONAL. ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, COMME INHIBITEURS DE MMP-13, POUR LE TRAITEMENT DE DIVERSES MALADIES.
TNTNSN02009A 2001-02-14 2002-02-13 Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant. TNSN02009A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26875601P 2001-02-14 2001-02-14

Publications (1)

Publication Number Publication Date
TNSN02009A1 true TNSN02009A1 (fr) 2005-12-23

Family

ID=23024328

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN02009A TNSN02009A1 (fr) 2001-02-14 2002-02-13 Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.

Country Status (15)

Country Link
US (1) US20030004172A1 (fr)
EP (1) EP1370562A1 (fr)
JP (1) JP2004518732A (fr)
BR (1) BR0207216A (fr)
CA (1) CA2433778A1 (fr)
DO (1) DOP2002000337A (fr)
GT (1) GT200200017A (fr)
HN (1) HN2002000029A (fr)
MX (1) MXPA03004926A (fr)
PA (1) PA8538301A1 (fr)
PE (1) PE20020957A1 (fr)
SV (1) SV2003000882A (fr)
TN (1) TNSN02009A1 (fr)
UY (1) UY27159A1 (fr)
WO (1) WO2002064598A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
OA12622A (en) * 2001-06-11 2006-06-12 Shire Biochem Inc Thiophene derivatives as antiviral agents for flavivirus infection.
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
EP1434585A1 (fr) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Inhibiteurs de metalloproteinase matricielle (mmp) a base d'alkyne
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
JP2006503811A (ja) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アロステリックカルボキシルマトリックスメタロプロテイナーゼ−13阻害薬とセレコキシブまたはバルデコキシブとの組み合わせ
BR0312727A (pt) * 2002-07-17 2005-04-19 Warner Lambert Co Combinação de um inibidor alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
CA2492391A1 (fr) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combinaison d'un inhibiteur allosterique de metalloproteinase matricielle 13 avec un inhibiteur selectif de cyclooxygenase-2, a l'exception du celecoxib ou du valdecoxib
MXPA05001783A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
WO2004014923A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloprotease bicycliques condenses avec la pyrimidinone
WO2004014378A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice
AU2003250465A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003253176A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
CA2492019A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives d'isoquinoleine utilises comme inhibiteurs de metalloprotease de matrice
WO2004014375A2 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloprotease bicycliques condenses
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
EP1539709A1 (fr) 2002-08-13 2005-06-15 Warner-Lambert Company LLC Derives d'azaisoquinoline utilises comme inhibiteurs de metalloproteases matricielles
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014869A2 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de 3,4-dihydropyrimidine-2-one 5,6-fondue, utilise comme inhibiteurs de metalloproteinase matricielle
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
WO2004014908A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloproteinases heterobicycliques
JP2005539020A (ja) 2002-08-13 2005-12-22 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としてのクロモン誘導体
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
DK1591446T3 (da) * 2003-01-29 2013-06-10 Takeda Pharmaceutical Thienopyrimidinforbindelser og anvendelse deraf.
JP2008094846A (ja) * 2003-01-29 2008-04-24 Takeda Chem Ind Ltd チエノピリミジン化合物およびその用途
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
WO2005002585A1 (fr) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combinaison d'un inhibiteur allosterique de la metalloproteinase-13 matricielle et d'un ligand au recepteur alpha-2-delta
WO2005016926A1 (fr) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Derives de pyrido[3,4-d]pyrimidine utiles comme inhibiteurs de la metalloproteinase-13 de matrice
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US7570259B2 (en) 2004-06-01 2009-08-04 Intel Corporation System to manage display power consumption
ATE405553T1 (de) 2004-12-08 2008-09-15 Bristol Myers Squibb Co Heterocyclische verbindungen als inhibitoren von faktor viia
CA2644996A1 (fr) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. Antagonistes du recepteur a2a de l'adenosine
ZA200901163B (en) * 2006-08-23 2010-08-25 Neurogen Corp 2-Phenoxy pyrimidinone analogues
CA2670788A1 (fr) * 2006-12-01 2008-06-12 Cv Therapeutics, Inc. Antagonistes du recepteur d'adenosine a2a
EP1939197A1 (fr) 2006-12-22 2008-07-02 Schwarz Pharma Ag Derivés de 8-éthinylxanthine comme antagonistes selectives du recepteur A2A
CA2685753A1 (fr) * 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Derives bicycliques de pyrimidine en tant que bloqueurs des canaux calciques
AR077898A1 (es) 2009-08-26 2011-09-28 Nycomed Gmbh Metilpirrolopirimidincarboxamidas
CA2855372C (fr) 2011-11-11 2022-03-22 Nimbus Apollo, Inc. Derives de 2,4-dioxo-thieno-[2,3-d]pyrimidinyle et compositions pharmaceutiques connexes utilisees comme inhibiteurs d'acc
SG11201602397XA (en) 2013-10-07 2016-05-30 Bayer Pharma AG Cyclic thienouracil-carboxamides and use thereof
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
JP2019503338A (ja) 2015-11-25 2019-02-07 ギリアド アポロ, エルエルシー 2,4−ジオキソ−1,4−ジヒドロチエノ[2,3−d]ピリミジンの誘導体を含む殺真菌組成物
US20170166583A1 (en) 2015-11-25 2017-06-15 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
WO2017091600A1 (fr) 2015-11-25 2017-06-01 Gilead Apollo, Llc Inhibiteurs de l'acc à base de pyrazole et utilisations associées
EP3380479B1 (fr) 2015-11-25 2022-12-07 Gilead Apollo, LLC Inhibiteurs d'acc à base de triazole et utilisations associées
KR102700008B1 (ko) 2016-03-02 2024-08-29 길리어드 아폴로, 엘엘씨 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법
WO2018041771A1 (fr) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft Thiéno-uraciles substitués par un groupe (1-méthylcyclopropyl)méthyle et leur utilisation
RU2019111357A (ru) 2016-09-23 2020-10-23 Байер Акциенгезельшафт N3-циклически замещенные тиеноурацилы и их применение
EP3600309B1 (fr) 2017-03-28 2022-06-22 Gilead Sciences, Inc. Combinaisons thérapeutiques pour le traitement de maladies du foie
CN110183464B (zh) * 2019-05-31 2021-08-31 淮阴工学院 一种抗癌化合物艾斯替尼及其合成方法和应用
KR102649886B1 (ko) * 2021-07-21 2024-03-22 충남대학교산학협력단 신규한 피리미딘-4-온 화합물 및 이를 포함하는 항암제 조성물
WO2024036183A1 (fr) * 2022-08-09 2024-02-15 Vanderbilt University Antagonistes de récepteurs 5-hydroxytryptamine de sous-type 2b

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155665A (en) 1961-04-26 1964-11-03 Searle & Co 4, 6-dialkyl-5, 7-diketothiazolo [4, 5-d] pyrimidine-2-carboxylic acid and derivatives thereof
US3277093A (en) 1965-08-02 1966-10-04 Searle & Co (optionally-2-substituted) 4-halophenyl-5, 7-diketo-6-alkylthiazolo[4, 5-d]pyrimidines
GB8601371D0 (en) 1986-01-21 1986-02-26 Beecham Group Plc Compounds
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US6048863A (en) * 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
WO1996014319A1 (fr) * 1994-11-08 1996-05-17 Takeda Chemical Industries, Ltd. Derives de thienopyridine ou de thienopyrimidine et leur utilisation
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
CN1066448C (zh) * 1996-06-06 2001-05-30 株式会社大塚制药工场 酰胺衍生物
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6166019A (en) * 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
NZ509809A (en) * 1998-08-28 2002-11-26 Astrazeneca Ab Thienol[2,3-d]pyrimidinediones which exhibit immunosuppressive activity
DE19940494C1 (de) * 1999-08-26 2001-02-15 Ibfb Gmbh Privates Inst Fuer B Mehrcyclische Pyrimidin-2,4(1H,3H)-dione mit funktionalisierten Alkylresten in 1- und/oder 3-Position, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US20050004111A1 (en) * 2003-01-03 2005-01-06 Aventis Pharma Deutschland Gmbh Selective MMP-13 inhibitors

Also Published As

Publication number Publication date
MXPA03004926A (es) 2005-02-14
HN2002000029A (es) 2003-02-14
US20030004172A1 (en) 2003-01-02
SV2003000882A (es) 2003-01-13
WO2002064598A1 (fr) 2002-08-22
GT200200017A (es) 2002-11-15
DOP2002000337A (es) 2002-08-15
UY27159A1 (es) 2002-09-30
CA2433778A1 (fr) 2002-08-22
PA8538301A1 (es) 2002-09-17
JP2004518732A (ja) 2004-06-24
PE20020957A1 (es) 2002-11-08
EP1370562A1 (fr) 2003-12-17
BR0207216A (pt) 2004-03-09

Similar Documents

Publication Publication Date Title
TNSN02009A1 (fr) Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02010A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN02011A1 (fr) Derives de pyrimidine bicycliques nouveaux, inhibiteurs de mmp, et compositions les contenant
TNSN02022A1 (fr) Triazolopyridines anti-inflammatoires nouvelles, et compositions les contenant
TNSN01149A1 (fr) Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions les contenant.
TNSN01150A1 (fr) Pyrimidine-2,4,6- triones inhibitrices de metalloproteinases, et compositions les contenant.
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
TNSN01048A1 (fr) Acides malonamiques et leurs derives, et compositions les contenant
TNSN98216A1 (fr) Derives d'acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00169A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TR200001973T2 (tr) 11 ß-halojen-7alfa-ile ikame edilmiş-estratrienler, bu 11ß-halojen-7alfa-ile ikame edilmiş-estratrienleri içeren farmasötik terkiplerin üretimi için yöntem ve ilaç üretiminde kullanımları.
TNSN01019A1 (fr) Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02015A1 (fr) Composes nouveaux antagonistes de ppar, et compositions les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9806296A (pt) Derivados de ácido sulfìnico e sua preparação e uso
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4